CME: SERMs: Managing the Most Bothersome Symptoms of Menopause

SERMs: Managing the Most Bothersome Symptoms of Menopause

SERMs: Managing the Most Bothersome Symptoms of Menopause

What role do SERMs play in the management of dyspareunia and vaginal dryness associated with vulvovaginal atrophy?

Available credits: 0.25

Time to complete: 15 Minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    The genitourinary syndrome of menopause (GSM) is a collection of signs and symptoms associated with decreased estrogen and other sex steroids. And since at least half of the more than 64 million postmenopausal women in the US will be affected by GSM symptoms, this activity will discuss the role of selective estrogen receptor modulators (SERMs) in managing two of the most bothersome symptoms: dyspareunia and vaginal dryness.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Lee Philip Shulman, MD, FACOG, FACMG
    The Anna Ross Lapham Professor in Obstetrics and Gynecology
    Feinberg School of Medicine of Northwestern University
    Chicago, IL

    Consulting Fees: Allergan, Biogix, Celula China, Cooper Surgical, Lupin Pharmaceuticals, Inc., Natera, Vermillion/Aspira                               
    Commercial Interest Speakers Bureau: AMAG Pharmaceuticals, Lupin Pharmaceuticals, Inc., Myriad, Vermillion/Aspira

    David J. Portman, MD
    Founder and Director Emeritus
    Columbus Center for Women’s Health Research
    Adjunct Faculty, The Ohio State University
    Department of Obstetrics and Gynecology
    Founder and CEO, Sermonix Pharmaceuticals
    Columbus, OH

    Grant/Research Support: Shionogi Pharmaceuticals, QuatRx Pharmaceuticals, Boehringer Ingelheim, Palatin Technologies, Endoceutics, TherapeuticsMD
    Consultant/Advisory Board: Duchesnay Pharmaceuticals, AMAG Pharmaceuticals, Agile Therapeutics, ITF Pharma
    Commercial Interest Speakers Bureau: AMAG Pharmaceuticals
    Salary and Stockholder: Sermonix Pharmaceuticals

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • Robert Schneider, MSW has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the pathophysiology underlying dyspareunia and dryness associated with VVA.
    • Define the underlying mechanisms of action of the various available SERMS.
    • Identify the indications and usage of the available SERMS.
    • Cite the scientific data regarding the benefits and risks of oral versus topical therapy for the management of dyspareunia and dryness of VVA.
  • Target Audience

    This activity is designed to meet the educational needs of obstetricians and gynecologists, family medicine physicians, internal medicine physicians, physician assistants, nurse practitioners, nurses, and certified nurse midwives.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by an independent educational grant from Duchesnay.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited.

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments


We’re glad to see you’re enjoying Omnia Education…
but how about a more personalized experience?

Register for free